Novo Nordisk wins FDA clearance for an elevated dosage of its GLP-1 agonist Wegovy, following recent analyst upgrades that highlight the strength of the obesity

FDA advisory committee votes 9-0 to support Moderna's mRNA-1010 flu vaccine, clearing the way for an August regulatory decision and expanding the company's mRNA

GLP-1 receptor agonists emerge as biopharma's most influential platform with applications expanding beyond weight loss to metabolic and cardiovascular condition

The US Trade Representative launches a Section 301 investigation into Germany's pharmaceutical price controls, alleging unfair burden on American R&D investment

Following March patent expiration for semaglutide, Indian GLP-1 drug prices collapsed 80% while market volume expanded tenfold, as local manufacturers including

FDA supports accelerated approval pathway for uniQure's AMT-130 Huntington's disease gene therapy, validating the approach after prior regulatory setbacks and p

FDA clears Beam Therapeutics' BEAM-304 investigational new drug application for phenylketonuria using base-editing technology, marking progress in rare genetic

Vertex Pharmaceuticals' CASGEVY gene-editing therapy demonstrates robust efficacy in pediatric patients with sickle cell and beta-thalassemia, validating invest

Moderna accelerates development of mRNA candidates for seasonal flu, RSV, and other infectious diseases, diversifying beyond COVID-19.

Analysis estimates Trump administration's negotiated drug pricing framework could yield $64 billion in savings over the decade, though claims face scrutiny on m

As GLP-1 market matures, competitive focus pivots to patient convenience and combination therapies addressing multiple metabolic pathways.

Indian pharmaceutical manufacturers position to capture significant share of $142 billion in near-term patent expirations, expanding beyond traditional generics

Next-generation obesity therapies focus on weight reduction without muscle loss, addressing adverse effects from current GLP-1 regimens.

India's government restricts 16 pharmaceutical combinations from use, affecting multiple domestic pharma companies and signaling regulatory tightening in the su

Competitive diabetes pipeline expands significantly with more than 200 pharmaceutical companies pursuing development programs, intensifying market competition.

Eli Lilly shares experience pullback despite dominant GLP-1 market position and valuations approaching $1,200, reflecting sector rotation headwinds.

Novel Parkinson's treatment approach demonstrates significant clinical benefit, offering potential disease modification in degenerative neurological condition.

Pfizer announces leadership transition in finance with CFO departure and interim successor appointment, signaling potential strategic shifts at the pharma giant